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Podocin is a key component of the slit diaphragm in the glo-
merular filtration barrier, and mutations in the podocin-encod-
ing gene NPHS2 are a common cause of hereditary steroid-re-
sistant nephrotic syndrome. A mutant allele encoding podocin
with a p.R138Q amino acid substitution is the most frequent
pathogenic variant in European and North American children,
and the corresponding mutant protein is poorly expressed and
retained in the endoplasmic reticulum both in vitro and in vivo.
To better understand the defective trafficking and degradation
of this mutant, we generated human podocyte cell lines stably
expressing podocinwt or podocinR138Q. Although it has been
proposed that podocin has a hairpin topology, we present evi-
dence for podocinR138Q N-glycosylation, suggesting that most of
the protein has a transmembrane topology. We find that N-gly-
cosylated podocinR138Q has a longer half-life than non-glycosy-
lated podocinR138Q and that the latter is far more rapidly
degraded than podocinwt. Consistent with its rapid degradation,
podocinR138Q is exclusively degraded by the proteasome,
whereas podocinwt is degraded by both the proteasomal and the
lysosomal proteolytic machineries. In addition, we demonstrate
an enhanced interaction of podocinR138Q with calnexin as the
mechanism of endoplasmic reticulum retention. Calnexin
knockdown enriches the podocinR138Q non-glycosylated frac-
tion, whereas preventing exit from the calnexin cycle increases
the glycosylated fraction. Altogether, we propose a model in
which hairpin podocinR138Q is rapidly degraded by the protea-
some, whereas transmembrane podocinR138Q degradation is
delayed due to entry into the calnexin cycle.
Nephrotic syndrome is clinically characterized by protein-
uria, edema, hypoalbuminemia, and hyperlipidemia, and is a
consequence of glomerular filtration barrier (GFB)2 dysfunc-
tion. The prognosis of steroid-resistant nephrotic syndrome
(SRNS) is poor, with a high proportion of patients rapidly devel-
oping end-stage renal disease, requiring dialysis or transplanta-
tion (1, 2). The GFB is comprised principally of podocytes, spe-
cialized epithelial cells that interdigitate at junctions known as
slit diaphragms (SDs). Mutations in the NPHS2 gene, encoding
the slit diaphragm (SD) protein podocin, are the most frequent
monogenic cause of SRNS in childhood (3, 4). Importantly, the
missense mutation NPSH2: R138Q (p.R138Q) accounts for 20%
of all SRNS-causing alleles in Europe and North America (4),
and is associated with an early-onset and rapidly progressing
form of the disease (5). In accordance with the severe clinical
phenotype, podocin p.R138Q (PodR138Q) is retained in the ER
of podocytes and does not reach the SD, thus impairing correct
functioning of the GFB (6, 7).
Podocin belongs to the stomatin and prohibitin homology
domain (PHB) protein family and is specifically expressed in
podocytes. It has been proposed that podocin acts as a molec-
ular scaffold for other SD proteins in lipid raft membrane sub-
domains. For example, podocin interacts with both nephrin
and CD2AP through its carboxyl terminus, and participates in
various signaling events at the SD (8 –10). Podocin has a pre-
dicted hairpin-loop topology, with both the N and C termini
facing the cytoplasm, and its hydrophobic domain anchored
either to the inner leaflet of the plasma membrane (PM) or to
the outer leaflet of the ER-membrane (7). However, an alterna-
tive transmembrane topology has been described for stomatin
and podocin, particularly when a conserved proline residue,
critical for the kink of the hairpin topology, found at position
118 in podocin, is mutated, and has been linked to N-glycosy-
lated forms of these proteins (11, 12). In addition, although the
stability and degradation of podocin has been associated with a
short internalization motif located in its C terminus and to an
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nisms of PodR138Q degradation are still unexplored. In this
study, we report the degradation pathways followed by
PodR138Q, which might aid to establish new therapeutic
strategies.
Results
PodocinR138Q is predominantly N-glycosylated
We generated two cell lines stably expressing two human
influenza hemagglutinin (HA) tags at the N terminus of wild-
type (WT) podocin (Podwt) and PodR138Q by lentiviral trans-
duction of a human podocyte cell line. Although both cell lines
expressed comparable levels of podocin mRNA (Fig. 1A), we
found significantly higher levels of Podwt protein in comparison
to PodR138Q (Fig. 1B). We then confirmed by immunofluores-
cence the expected subcellular localization at the PM for Podwt
(co-localization with the wheat germ agglutinin, WGA) and at
the ER for PodR138Q (a reticular pattern staining partially colo-
calizing with calnexin) (Fig. 1C) (7). We demonstrated that nei-
ther Podwt nor PodR138Q stable overexpression caused ER stress
as evidenced by the lack of up-regulated levels of BiP protein
(GRP78), an ER-chaperone widely used as an ER-stress indica-
tor (Fig. S1) (15–17). As positive controls of ER stress induction
caused by misfolded mutant proteins, we generated human
podocyte cell lines stably expressing V5-tagged nephrinwt
(Nephwt) or nephrinS366R (NephS366R), because this latter
mutant has been previously shown to induce ER stress (Fig.
S1A) (18).
Interestingly, we observed three specific bands for both
Podwt and PodR138Q on podocin immunoblots. The fastest
migrating band (lower band) was predominantly observed in
Podwt protein extracts, whereas the slowest migrating band
(upper band) was predominantly found in PodR138Q extracts
(Fig. 1B). To determine whether the upper bands in the WT and
mutant podocin triplets were N-glycosylated forms, we either
inhibited N-glycosylation by treating cells with tunicamycin, or
treated cell lysates with peptide:N-glycosidase F (PNGase F) to
digest N-glycan groups. Upper and middle bands of the podocin
triplets disappeared using both strategies (Fig. 1D) allowing us
to define the upper, middle, and lower bands of the podocin
triplets as double-glycosylated (dg), monoglycosylated (mg),
and non-glycosylated (ng) podocin. To test whether the differ-
ence in protein levels of Podwt and PodR138Q was due to these
Figure 1. Stably over-expressed podocinR138Q is largely N-glycosylated, a feature shared only with other ER-retained podocin mutants. qRT-PCR (A),
Western blot (B, D, and E), and immunofluorescence analysis (C) comparing podocin expression levels, protein band distribution, and subcellular localization,
respectively, in 2HA-Podwt and 2HA-PodR138Q expressing podocyte cell lines. B, ng, non-glycosylated podocin; mg, mono-glycosylated podocin; dg, double-
glycosylated podocin. Quantification of total podocin (ng, mg and dg) from three independent experiments are shown as mean  S.D. *, p  0.05. HA
monoclonal antibody was used to identify podocin and -actin served as loading control. C, polyclonal anti-podocin AP-P35 (Pod) and monoclonal calnexin
AF18 (Cnx) were used as primary antibodies. Cell membrane and nuclei were labeled with WGA and Hoechst (H), respectively. Scale bar  30 m. D, cells were
treated overnight with 10 g/ml of tunicamycin (Tm) to impair N-glycosylation (upper immunoblot). Alternatively, cell lysates were treated with PNGase F, an
enzyme that digests N-glycans from glycoproteins (lower immunoblot). Polyclonal AP-P35 or monoclonal anti-HA were used to immunoblot podocin. E,
immunoblots of different podocin mutants known to possess different subcellular localizations. ER, endoplasmic reticulum–retained podocin mutants; V,
vesicular podocin mutants; PM, plasma membrane localized podocin mutants.
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differential glycosylation patterns, we also created podocyte
cell lines stably expressing HA-tagged Podwt and PodR138Q
bearing mutations in the amino acid residues required for
N-glycosylation, Asn199 and Asn355 (Podwt(N199Q,N355S) and
PodR138Q(N199Q,N355S)). Immunoblots of protein extracts
from these cells revealed that although the podocin triplet
disappears with mutation of residues Asn199 and Asn355 (Fig.
S1B), glycosylation alone does not account for the differ-
ences in protein levels of Podwt and PodR138Q, as there
remains increased amounts of Podwt(N199Q,N355S) compared
with PodR138Q(N199Q,N355S).
Our results showed that the mutant PodR138Q was predomi-
nantly N-glycosylated, similarly to PodP118L (12), another ER-
retained podocin mutant, suggesting that the majority of intra-
cellular PodR138Q has a transmembrane topology (11, 12).
However, a small part of the Podwt pool was also glycosylated,
consistent with the observations of WT podocin and stomatin
by other authors (11, 12). We tested by immunoblot the protein
expression pattern of a series of podocin mutants that present
different subcellular localizations, confirming that only ER-re-
tained mutants, such as PodR168C, were enriched in N-glycosy-
lated forms (Fig. 1E).
PodocinR138Q has a shorter half-life than Podwt and is rapidly
degraded by the proteasome
To investigate whether the difference in protein levels of
Podwt and PodR138Q was due to a higher degradation rate of the
mutant protein, we determined the half-life (t1⁄2) of both pro-
teins using a cycloheximide time course experiment, quantify-
ing separately the glycosylated and non-glycosylated forms
(Fig. 2). No differences were observed between the t1⁄2 of the
three Podwt forms, whereas a drastically reduced t1⁄2 was
detected for ng-PodR138Q when compared with Podwt (7-fold).
Consistent with this finding, we also demonstrated that the t1⁄2
of the glycosylation mutant PodR138Q(N199Q,N355S) was also
reduced around 7-fold compared with Podwt(N199Q,N355S)
(Fig. S2). Interestingly, ng-PodR138Q (i.e. hairpin-like to-
pology) appeared to be degraded faster than the N-glycosy-
lated forms of PodR138Q (i.e. those with transmembrane to-
pology), implying that the hairpin-like structure is more
exposed to the intracellular degradative machinery (Fig. 2
and Fig. S2).
Because ng-PodR138Q is degraded very quickly, we hypothe-
sized that the proteasome was mediating its clearance. We
therefore used the reversible proteasome inhibitor bortezomib
(Bz) to perform dose-response and time course experiments
(Fig. 3). We observed that ng-PodR138Q accumulated in a dose-
dependent manner, whereas levels of ng-Podwt increased
significantly only at the highest Bz dose of 1 M (Fig. 3A). Con-
sistent with their longer t1⁄2, both glycosylated Podwt and glyco-
sylated PodR138Q were not increased at any dose of Bz after 2 h
(Fig. 3A). Thus, we next performed an overnight time course
(16 h) using the lowest effective dose of Bz (0.1 M) (Fig. 3B).
We found that only ng-PodR138Q accumulated with time, and,
most interestingly, the balance between ng- and dg-PodR138Q
was inverted, thus after 16 h the proportions of each PodR138Q
band resembled the proportions of each Podwt band in podocin
immunoblots (Fig. 3B, colored graph). Levels of all forms of
Podwt were increased only at the longest time points. Similar
findings were observed when we performed an overnight Bz
time course on cells expressing the glycosylation mutants
Podwt(N199Q,N355S) and PodR138Q(N199Q,N355S), with protein
levels of the WT protein only significantly increased at the
longest time point of 16 h, and a trend for levels of
PodR138Q(N199Q,N355S) to accumulate in the presence of 0.1 M
Bz (Fig. S3A). The increased amount of Podwt and PodR138Q
after an overnight treatment with 0.1 M Bz was confirmed by
immunofluorescence analysis (Fig. 3C). As expected, a sus-
tained exposure to Bz led to ER stress, as indicated by BiP
induction (Fig. 3C), but to a higher extent in cells expressing
PodR138Q (Fig. S3). Therefore, we concluded that the protea-
some contributes to the degradation of both Podwt and
PodR138Q, but more actively for ng-PodR138Q.
Figure 2. PodocinR138Q has a short half-life. Immunoblot analysis of the time course of podocin degradation after inhibition of protein synthesis with
cycloheximide (CHX) (25 M) in podocyte cell lines. Densitometry data from three independent experiments are represented as mean  S.D. Half-lives were
estimated by fitting a one-phase exponential decay curve to the data, as in the graph shown for ng-Podwt and ng-PodR138Q, and are summarized in the table.
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PodocinR138Q is not degraded by lysosomes
Because protein degradation proceeds via two major routes:
the proteasomal and the autophagic-lysosomal pathways, we
investigated whether lysosomal degradation contributes to
Podwt and PodR138Q proteolysis. We therefore treated the cells
with ammonium chloride (NH4Cl), a weak base known to
inhibit lysosomal proteases. NH4Cl treatment significantly
increased levels of the ng-Podwt protein fraction and levels of
Podwt(N199Q,N355S), implying that the lysosomal machinery is
involved in Podwt degradation but not in PodR138Q proteoly-
sis; indeed, we observed levels of both PodR138Q and
PodR138Q(N199S,N355S) to fall after a 16-h NH4Cl treatment (Fig.
4A and Fig. S4B). Then, by confocal microscopy, we confirmed
the absence of PodR138Q in the late endosome/lysosome com-
partment labeled with CD63 (Fig. 4B). Conversely, Podwt is pre-
dominantly present in this compartment, as already described
(13). Taken together, our data suggest that Podwt is mainly
degraded in lysosomes, in contrast to PodR138Q, which is exclu-
sively degraded by the proteasome.
PodocinR138Q enhanced interaction with calnexin
Misfolded N-glycosylated proteins located in the ER mem-
brane are submitted to a strict quality control (QC) by the so-
called calnexin (Cnx) cycle, being retained by the 90-kDa chap-
erone Cnx until they reach their native conformation or are
otherwise sent for ER-associated degradation (ERAD). We
hypothesized that if PodR138Q is mostly N-glycosylated and pos-
sesses a transmembrane topology, interaction with Cnx may be
a mechanism of PodR138Q ER retention, as has already been
described for some nephrin mutants (18). Immunoblots of
Figure 3. PodocinR138Q is degraded by the proteasome. Podocyte cell lines were treated with the proteasome inhibitor Bz or vehicle (DMSO) and processed
for immunoblot (A and B) or immunofluorescence analysis of podocin (C). A, Bz dose-response (0.02 to 1 M) after 2 h of treatment. B, time course of podocin
after addition of 0.1 M Bz. A and B, podocin was identified using AP-P35 (Pod) primary antibody. BiP analysis was included to track ER stress (B). Quantification
of ng bands is shown in the lower graphs in A and in the middle graphs in B. Color graphs in B represent the percentage amount of each podocin band relative
to total podocin. Quantitative results are shown as mean  S.D. (n  3). Asterisks refer to non-stimulated cells (ns or 0 h). *, p  0.05 and **, p  0.01. C, podocin
was detected by incubation with monoclonal HA primary antibody (in green). Hoechst nuclei labeling was included (in blue). All images were taken using the
same confocal microscope settings to allow comparison of the intensity of fluorescence. Scale bar  40 m.
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HEK293T cells transfected with HA-tagged WT podocin and
the two ER-retained mutants, PodR138Q and PodR168C (7),
showed that similarly to our findings from podocyte cell lines
stably expressing Podwt and PodR138Q podocin was present as
three differentially glycosylated species (Fig. 5A). Co-immuno-
precipitation studies revealed an interaction between Cnx and
both WT and mutant podocin, with the mutant proteins inter-
acting to a greater extent compared with the WT protein (Fig.
5A). That we found Cnx also interacted with Podwt was not
surprising, because HA immunoprecipitation enriched a cer-
tain proportion of N-glycosylated Podwt (Fig. 5A, upper panel).
Surprisingly, ng-podocin, WT, and mutants, also co-immuno-
precipitated with Cnx, suggesting that hairpin podocin might
interact with Cnx either indirectly, perhaps through oligomer-
ization with the podocin transmembrane fraction via its N
terminus (19), or directly, through membrane or cytosolic
domains. To test whether impairing the interaction of PodR138Q
with Cnx would allow its ER exit and promote membrane local-
ization, we first treated the cells with castanospermine (Cst), a
specific inhibitor of glucosidases I and II that prevents the sugar
trimming necessary for the recognition of the substrate protein
N-glycan groups by the lectin domain of Cnx. Cst decreased
Cnx interaction with Podwt, but not with PodR138Q (Fig. 5B),
suggesting that PodR138Q interaction with Cnx is N-glycan inde-
pendent. Similar results were obtained when these experiments
were performed using cells expressing glycosylation mutants
Podwt(N199Q,N355S) and PodR138Q(N199Q,N355S) (Fig. 5C), sup-
porting the idea that the interaction with Cnx is more lectin
dependent for Podwt than for PodR138Q. Finally, we found that
introduction of p.N199Q and p.N355S substitutions into the
PodR138Q mutant in podocytes did not prevent its ER retention,
implying that suppression of the N-glycan-dependent interac-
tion with Cnx is not sufficient to bring PodR138Q to the PM (Fig.
S4A), and supporting the idea that podocin is capable of lectin-
dependent binding to Cnx.
Glycosylated podocinR138Q enters the calnexin cycle
Because we observed PodR138Q(N199Q,N355S) is still able to
interact with Cnx, we next knocked-down Cnx in the two stable
podocyte cell lines using siRNA (Fig. 6A and Fig. S5A). Inter-
Figure 4. PodocinR138Q is not degraded in the lysosomal compartment. A, time course immunoblot analysis of podocin content after the impairment of
lysosomal degradation with NH4Cl (50 mM). The polyclonal antibody AP-P35 (Pod) was used to immunolabel podocin. Graphs show densitometry quantifica-
tion of ng-podocin in three independent experiments. Data are normalized to -actin and then to non-treated cells (0 h). Asterisks refer to 0 h. **, p  0.01. B,
double immunofluorescence staining of podocin (AP-P35; green) and the lysosome/late endosome marker CD63 (cyan). Nuclei labeling by Hoechst is included
(blue). Scale bar  10 m.
PodocinR138Q quality control and ERAD



























estingly, we observed that levels of N-glycosylated forms of
PodR138Q were decreased upon Cnx knockdown, in contrast
to levels of ng-PodR138Q, which were significantly increased
(Fig. 6A, colored graph), suggesting that Cnx may play a role in
stabilization of the transmembrane form of N-glycosylated
PodR138Q, or indeed, that interaction with Cnx promotes glyco-
sylation of PodR138Q. However, in support of the former state-
ment, the total amount of PodR138Q was slightly decreased after
Cnx knockdown, suggesting that interaction with Cnx might
delay PodR138Q degradation (Fig. 6A, lower graph). Next, we
treated cells with kifunensine (Kif), a drug that inhibits the
activity of -mannosidase I, and thus the mannose trimming
that tags Cnx substrates for ERAD (Fig. 6B). Here, our results
were precisely the opposite to those obtained upon Cnx knock-
down, that is, levels of ng-PodR138Q were significantly reduced,
whereas levels of dg-PodR138Q were increased (Fig. 6B, colored
graph). Furthermore, the total amount of PodR138Q was aug-
mented after 4 h of treatment (Fig. 6B, lower graph), demon-
strating that Kif treatment partially prevented PodR138Q
degradation. These last data support the idea that only N-gly-
cosylated, and thus transmembrane PodR138Q, enters the Cnx
cycle before being directed to ERAD. Finally, we observed by
immunofluorescence that neither knockdown of Cnx nor
blocking entry into the ERAD pathway with Kif were sufficient
to target PodR138Q to the PM (data not shown). No significant
changes on Podwt levels were observed upon Cnx knockdown,
but 4 h of Kif treatment did increase the levels of dg-Podwt,
suggesting that glycosylated Podwt may also enter the Cnx cycle
(Fig. S5B).
Bortezomib partially re-addresses PodR138Q to the plasma
membrane
While studying the proteasomal degradation of PodR138Q, we
observed by immunofluorescence that a fraction of PodR138Q
was localized, after Bz exposure, to thin filopodia PM protru-
sions, similarly to Podwt in untreated cells, whereas PodR138Q
was completely absent from these structures before treatment
(Fig. 7A). Targeting of PodR138Q to filopodia, quantified as the
percentage of WGA-positive filopodia that were also positive
for podocin, revealed that Bz treatment increased plasma mem-
brane targeting of PodR138Q, as soon as 2 h after Bz treatment,
although levels did not reach those of Podwt (Fig. 7A, graph).
Figure 5. PodocinR138Q has an enhanced interaction with calnexin. A–C, co-immunoprecipitation analyses of podocin and calnexin in HEK293T cells. A,
co-immunoprecipitation of HA-tagged Podwt, PodR138Q, PodR168C, or an empty HA lentiviral vector (pLenti-HA) with Cnx. B, cells were treated with the
glucosidase I and II inhibitor castanospermine (Cst; 500 M, 16 h) before performing HA-immunoprecipitation to study the lectin-dependent interaction of Cnx
with Podwt and PodR138Q. C, co-immunoprecipitation of Cnx with podocin in cells overexpressing HA-tagged Podwt and PodR138Q with or without mutated
N-glycosylation sites Asn199 and Asn355. A–C, monoclonal anti-HA and anti-Cnx AF18 were used to identify podocin and Cnx, respectively. Graphs represent the
densitometry quantification of Cnx when podocin is immunoprecipitated (IP HA). Data are normalized to total immunoprecipitated podocin (HA triplet in IP HA)
and represent at least three independent experiments. *, p  0.05.
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We also observed a decreased interaction of PodR138Q with Cnx
in HEK293T cells treated with Bz, which may serve as an indi-
cator of PodR138Q accumulation outside the ER (Fig. 7B).
Because we do not see PodR138Q at the PM (Fig. 7A) and the
glycosylated forms of PodR138Q seem to be insensitive to Bz
(Fig. 3), we hypothesize that only ng-PodR138Q is reaching the
PM upon Bz treatment. Taking into account all our data we
propose a scheme depicting a dynamic interchange between
the hairpin and the transmembrane topology at the different
steps of ER QC and subsequent ERAD (Fig. 7C). Briefly, hairpin
PodR138Q is detected by the cytoplasmic QC machinery and
rapidly degraded by the proteasome. In the meantime, N-gly-
cosylated transmembrane PodR138Q enters the Cnx cycle to be
eventually sent for ERAD. Because proteasomal degradation
takes place in the cytosol, transmembrane PodR138Q would lose
its N-glycan groups at some point between retrotranslocation
and proteasomal degradation (20 –22), possibly adopting a
hairpin topology when exposed to the cytosol. Bz treatment
would then inhibit the degradation of ng-PodR138Q, giving it the
chance to follow the secretory pathway and reach the PM.
Discussion
Despite p.R138Q being the most common podocin mutation
causing SRNS in European and North American children (4),
little is known about how this mutation affects podocin stability
and degradation. In this study, we have found that human
PodR138Q, when stably overexpressed in human podocyte cell
lines, is clearly resolved as a triplet on immunoblots. The upper
bands of these triplets correspond to N-glycosylated forms,
which is particularly intriguing because it implies that the C
terminus of most PodR138Q is inside the ER lumen. N-Glycosyl-
ation, and evidence of transmembrane topology, has been
already described for stomatin, for the short isoform of podocin
and for podocinP118L, another ER-retained podocin mutant (11,
12, 23). Whereas Pro118, an amino acid that is highly conserved
throughout the stomatin family, is located within the hydro-
phobic intramembrane region and is responsible for the kink of
the hairpin topology (12), Arg138 and Arg168, which are also
very well conserved, are located within the PHB domain, far
away from this region. Nevertheless, we hypothesize that mis-
sense mutations in the PHB region may also destabilize podocin
hairpin topology, the folding of which is already intrinsically
inefficient (11). Indeed, most of the missense mutations affect-
ing the PHB domain typically result in ER-retention (7), and
only podocin mutants that are known to be retained in the ER
present N-glycosylation levels comparable with PodR138Q. The
switch in topology has important implications for the stability
and the degradation of PodR138Q. We found the glycosylated
PodR138Q forms to be more stable than ng-PodR138Q. The latter,
with a hairpin structure, can be rapidly degraded by the protea-
some. In contrast, we found evidence that the transmembrane
isoform of PodR138Q enters the calnexin cycle, which may
explain its longer t1⁄2. Of course, it remains that glycosylation
and deglycosylation events may be affecting the observed dif-
ferences in stability of the different glycosylated podocin spe-
Figure 6. PodocinR138Q enters the calnexin cycle. A and B, immunoblot analysis of podocin (HA) after Cnx knockdown (siCnx) (A) or impairment of Cnx cycle
exit through the inhibition of -mannosidase I with kifunensine (Kif) (B) in HA WT and R138Q stably expressing podocyte cell lines. A, two siRNA oligonucleo-
tides against Cnx were tested, alone (siCnx (1) and siCnx (2)) or in combination (siCnx (1  2)). Luciferase siRNA (siLuc) served as control. Cnx protein amount was
quantified to confirm Cnx knockdown (upper left graph). B, effect of kifunensine on podocin protein content. ns, non-stimulated cells. A and B, podocin was
quantified as the relative percentage amount of each band within the triplet (color graph) or as total protein (the three bands altogether; lower graph). *, p 
0.05 and **, p  0.01.
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cies, and undoubtedly these processes are also contributing
to our results. That said, based on our experiments with
Podwt(N199Q,N355S) and PodR138SQ(N199Q,N355S), which show
these proteins behave in the same way as ng-Podwt and
ng-PodR138Q, we believe that glycosylation of ng-podocin is not
contributing to the observed increased stability of the glycosy-
lated species, and in fact the longer t1⁄2 of mg- and dg-PodR138Q
are due to decreased exposure to the intracellular degradative
machinery. According to our results, transmembrane PodR138Q
would be exclusively located in the ER as an intermediary of
PodR138Q QC, and is there stabilized by interaction with Cnx.
Indeed, in contrast to what has been shown for PodP118L (12),
we did not find PodR138Q to be localized at the PM by immuno-
fluorescence. This same model may apply for misfolded Podwt,
because it also interacts with Cnx and its glycosylated forms are
enriched after Kif treatment. Nevertheless, the increased levels
of Podwt following NH4Cl addition, together with the lack of
response to Bz at short times, suggest that Podwt is mainly
degraded in the endosome/lysosome compartment, a finding in
accordance with results from other authors (13).
Cnx recognizes a complex code of glucose and mannose
trimming in the N-glycan groups of its substrate proteins (21,
Figure 7. Bortezomib partially re-addresses podocinR138Q to the plasma membrane. A, immunofluorescence analysis showing PodR138Q (green) in the
presence of filopodia, through colocalization with the PM marker WGA (red), after a 2-h treatment with Bz (0.1 M) or vehicle (DMSO). Podwt co-localization with
WGA is included as a positive control. Hoechst nuclei labeling (H) is also shown (blue). Scale bar  10 m. Image analysis of the WGA co-localization with
podocin only at filopodia was obtained through the quantification of regions of interest (ROIs) that carefully delimit cell perimeters. Graph corresponds to the
quantification of one representative experiment. One-way analysis of variance followed by Dunnett’s post-test was used as statistical analysis. **, p  0.01 and
***, p  0.001. B, co-immunoprecipitation (IP HA) of HA-podocin and Cnx after Bz addition (16 h at 0.1 M). The graph represents the densitometry quantifi-
cation of Cnx when podocin is immunoprecipitated. Data are normalized to total immunoprecipitated podocin (HA triplet) and represent to at least three
independent experiments. ***, p  0.001. C, schematic summarizing the influence of different treatments on PodR138Q topology and subcellular localization.
Red and green arrows indicate a dynamic change to the transmembrane “wrong” or hairpin “right” topology, respectively. Numbers circled in yellow: (1) there is
an imbalance of hairpin PodR138Q toward a transmembrane topology, (2) decreasing PodR138Q interaction with Cnx through siCnx transfection favors the
hairpin topology, (3) stabilization of PodR138Q interaction with Cnx, through inhibition of Cnx cycle exit with Kif, enhances podocin transmembrane topology,
and (4) inhibition of PodR138Q proteasomal degradation with Bz increases the proportion of hairpin PodR138Q and is the only treatment that allows partial
relocalization to the PM. EC, extracellular matrix; PM, plasma membrane; C, cytosol.
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24 –26). The fact that PodR138Q topology and degradation is
sensitive to mannose trimming implies that most probably
there is an interaction with Cnx through its N-glycan groups.
This result apparently contradicts the data obtained by the spe-
cific inhibition of the N-glycan-dependent interaction of Cnx
with PodR138Q, because the interaction with Cnx was not
decreased. Nevertheless, there is an increasing amount of liter-
ature suggesting alternative sites of interaction to the lectin
domain of Cnx (i.e. the Cnx transmembrane domain), espe-
cially in the case of mutant proteins (27–29). An interesting
proposal is that there are at least two different types of interac-
tion occurring sequentially or simultaneously; one carbohy-
drate based, through the N-glycan groups, and one peptide
based, outside the Cnx lectin domain (30 –32). This would
explain why inhibiting lectin binding is insufficient to impair
PodR138Q interaction with Cnx. In contrast, Cnx interaction
with Podwt seemed to be more dependent on the N-glycan
groups, even though Podwt is predominantly non-glycosylated.
However, we cannot rule out a second Cnx interaction site also
for Podwt, because deletion of N-glycan sites did not completely
impair the interaction with Cnx and ng-Podwt also co-immu-
noprecipitated with Cnx. Finally, it is tempting to speculate that
N-glycosylation and interaction with Cnx may be part of nor-
mal podocin biosynthesis and initial folding, and not only a
mechanism of podocin quality control. In fact, Cnx is part of the
ribosome–translocon complex and its initial association to nas-
cent glycoproteins is usually co-translational (33, 34).
The targeting of PodR138Q to the cell membrane using
chemical chaperones as glycerol, trimethylamine-N-oxide, and
DMSO has already been reported in transiently transfected
human podocytes (35). Nevertheless, there is still no treatment
available for SRNS patients carrying the p.R138Q mutation.
Here, we report the therapeutic potential of Bz (Velcade), a
reversible inhibitor of the 26S proteasome that has been
approved and successfully used in multiple myeloma therapy
(36, 37). PodR140Q, the mouse equivalent to PodR138Q, is poorly
expressed in the glomeruli of the constitutive Nphs2R140Q/R140Q
knock-in mice (6), similarly to our findings in podocyte cell
lines. By studying PodR138Q t1⁄2 and the degradation pathways it
follows, we have found that low intracellular levels of PodR138Q
are due to rapid proteasomal degradation. Bz not only increases
PodR138Q protein levels, but allows a significant amount of
PodR138Q to reach the PM, at least at filopodia. This could be
simply caused by an overflow from the ER, because 2 h of Bz
treatment already quadruples PodR138Q protein levels. Indeed,
proteasomal inhibition has been found to inhibit the retro-
translocation of most ERAD substrates, thus giving them the
chance to remain in the secretory pathway (21, 38, 39). Alter-
natively, because de-glycosylation by cytoplasmic peptide:N-
glycanases (PNGases) is an additional step in glycoprotein
ERAD (40), Bz would specifically rescue the ng-PodR138Q
already targeted for proteasomal degradation. In support of this
idea, a promising effect of Bz is that it enriches the ng-PodR138Q
fraction corresponding to the potentially functional hairpin
topology of PodR138Q at the SD. A successful therapy would
need not only to bring PodR138Q to the PM, but also promote its
hairpin topology. Interestingly, Bz has been reported to rescue
other misfolded mutant proteins back to the PM in vitro and in
vivo (42). Additionally, second generation proteasomal inhibi-
tors are currently being tested in clinical trials with less severe
side effects than those of Bz, such as neurotoxicity or lym-
phopenia (43). Altogether, although we lack in vivo studies, we
propose that increasing ng-PodR138Q protein levels through the
inhibition of the proteasomal degradation may be a reasonable
strategy to treat patients with p.R138Q mutation and possibly
with other ER-retained podocin mutations.
Experimental procedures
Plasmids, cell culture, and establishment of lentiviral cell lines
Human podocin-coding constructs were generated as
described by Tory et al. (44). Human wildtype NPHS1 cDNA,
encoding nephrin, was amplified from the construct described
by Philippe et al. (6) and subcloned into NotI and SpeI sites of
LentiORF pLEX-MCS (Open Biosystems). Thus, the encoded
proteins consist of podocin with two hemagglutinin tags (2HA)
fused to its N terminus, and nephrin with a V5 tag fused to its N
terminus. Site-directed mutagenesis (QuikChange kit, Strat-
agene) was used to generate the missense mutations used in this
study: p.R138Q, p.R168C, p.N199Q, p.N355S for podocin, and
p.S366R for nephrin. All constructs were verified by Sanger
sequencing. A human immortalized podocyte cell line (AB8/
13), obtained by transfection of the temperature-sensitive
mutant tsA58 of the SV40-T-antigen-encoding gene, was
kindly provided by M. A. Saleem (45). Stable podocyte cell lines
were obtained by transduction of the above cell line with lenti-
viral vectors expressing either podocin (wildtype or mutants) or
nephrin (wildtype or mutants) at a multiplicity of infection of 1,
and subsequently selected by puromycin (2 g/ml). Podocytes
were cultured at 33 °C with 7% CO2 in RPMI 1640 medium
supplemented with 10% fetal bovine serum, insulin/transferrin/
selenium, glutamine, and penicillin/streptomycin (all from Life
Technologies). At this growth-permissive temperature, podo-
cytes are proliferating and undifferentiated, and do not express
either endogenous podocin or nephrin. HEK293T cells were
maintained in Dulbecco’s modified Eagle’s medium supple-
mented with 10% fetal bovine serum, glutamine, and penicillin/
streptomycin (all from Life Technologies). Cell lines used in
this study were tested mycoplasma-free.
Antibodies, enzymes, and chemical compounds
PNGase F was purchased from New England BioLabs. Tuni-
camycin, cycloheximide, bortezomib, NH4Cl, castanosper-
mine, and kifunensine were purchased from Sigma. The
commercial antibodies used were as follows: mouse anti-HA
(HA.11 clone 16B12, Covance), mouse anti-calnexin (Cnx)
(clone AF18, Enzo Life Sciences), mouse anti-CD63 (clone
H5C6, DSHB), and mouse anti-calnexin (clone C5C9, Cell Sig-
naling Technology). Rabbit anti-podocin AP-P35 (Pod) was
described previously (46). Alexa Fluor 555-conjugated wheat
germ agglutinin (WGA555) (W32464, Life Technologies) was
used to stain the plasma membrane. Rat IgG2a (isotype control
clone 2H3, MBL) for immunoprecipitation control experi-
ments was purchased from MBL. Secondary antibodies for
immunoblotting were sheep anti-mouse and donkey anti-rab-
bit HRP-conjugated antibodies (GE Healthcare UK). Secondary
antibodies for immunofluorescence were donkey anti-rabbit
PodocinR138Q quality control and ERAD



























and anti-mouse Alexa Fluor 488- and 647-conjugated antibod-
ies (Life Sciences).
siRNA experiments
The following siRNAs were used to transfect podocyte cell
lines stably expressing podocin to specifically knockdown the
human CNX (calnexin) gene: siRNA-1, 5-AAGACGAUAC-
CGAUGAUGAAA-3 and siRNA-2, 5AAUGUGGUGGUGC-
CUAUGUGA-3. siRNA against the luciferase gene (Luc,
5-GCCAUUCUAUCCUCUAGAGGAUG-3) was used as a
siRNA control. siRNAs were transfected using Lipofectamine
RNAiMAX Reagent (Invitrogen) at a concentration of 20 nM
and the efficacy of siRNA was tested 3 days after transfection.
Quantitative real-time PCR
Total RNA was extracted from podocyte cell lines using the
Qiagen extraction RNeasy kit (Qiagen) and treated with
DNase I. One g of total RNA was reverse-transcribed using
SuperScript II according to the manufacturer’s protocol (Invit-
rogen). The relative expression levels of the studied mRNAs
were determined by quantitative real-time PCR using Absolute
SYBR Green ROX Mix (ABgene) with the following specific
primers for human NPHS2: forward (929F) 5-GGCTGA-
AGCGCAAAGACAAG-3 and reverse (988R) 5-GCAGC-
CTTTTCCGCTTCTG-3. Human hypoxanthine phosphori-
bosyltransferase (Hprt) was used as an internal standard. Data
were analyzed with the 2Ct method (47).
Immunofluorescence
Podocytes were cultured on type I collagen-coated coverslips
and either transiently transfected using FuGENE HD (Pro-
mega) or treated with different drugs. When appropriate, cells
were washed once with cold PBS, incubated with Alexa Fluor
555-conjugated WGA (1:600) for 15 min at 4 °C, and then fixed
with ice-cold ethanol for 5 min. Fixed cells were blocked with
1	 PBS, 1% BSA for 30 min before incubation with mouse
anti-HA primary antibodies (1:500) or rabbit anti-podocin
AP-P35 (1:300) when combined with mouse anti-calnexin
(1:500) or mouse anti-CD63 (1:200), followed by Alexa Fluor
488- or 647-conjugated secondary antibodies (1:200). Confocal
images were captured using a 	40 oil objective attached to a
Leica SP8 confocal microscope. At least five random fields, with
the only condition that filopodia were well visualized in the
WGA channel, were considered for the quantification of the
percentage area of WGA colocalization with podocin using
ImageJ 1.48i software. Masks were carefully created to specifi-
cally quantify the labeling of the filopodia. Confocal settings
and Image J thresholds were kept the same.
Immunoblotting
Proteins from podocyte cell lines were extracted in lysis
buffer containing 150 mM NaCl, 50 mM Tris-HCl, pH 7, 0.5%
Triton X-100 with CompleteTM protease inhibitors (Roche
Applied Science). Protein dosage was then performed using the
BCA protein assay kit (Thermo Scientific). Fifty micrograms of
protein were loaded on a 10% SDS-PAGE gel and transferred to
a nitrocellulose membrane. Membranes were blocked in 5%
skimmed milk in 1	 Tris-buffered saline, 0.1% Tween 20
(TBST) for 1 h and incubated with primary antibodies at a
1:1,000 dilution. After washing, membranes were incubated
with HRP-conjugated secondary antibodies diluted 1:10,000 in
TBST, 5% milk for 1 h at room temperature. Signals were
detected using ECL reagents (Amersham Biosciences) and
acquired in a Fusion Fx7 darkroom (Vilber Lourmat). Densi-
tometry quantification was performed using Bio-1D software.
Immunoprecipitation
HEK293T cells were transiently transfected with HA-tagged
WT podocin and mutants using calcium phosphate. Forty-
eight h post-transfection, cells were lysed in 150 mM NaCl, 25
mM Tris-HCl, pH 8, 0.5% Triton X-100 with protease inhibi-
tors, and HA-tagged podocin was immunoprecipitated using
the MACSTM Epitope Tag Protein Isolation Kit (Miltenyi Bio-
tec). Briefly, fresh lysates (1–1.5 mg of protein) were incubated
either with mouse anti-calnexin antibodies, followed by a
30-min incubation with magnetic beads-coupled to protein A,
or directly with magnetic beads coupled to a HA antibody. A rat
IgG2a isotype control was included to discard unspecific
interactions. Immunoprecipitated proteins were isolated
using MACS Separation Columns in a magnetic MACS
separator and subsequently eluted with 1	 Laemmli buffer.
Lysates and immunoprecipitated samples were subjected to
immunoblot.
Statistical analyses
All immunoblots were normalized to -actin and then to the
corresponding control group or the immunoprecipitated pro-
tein in control conditions. Statistical analysis of at least three
independent experiments was done using the one-sample two-
tailed t test (41) or a one-way analysis of variance, p values: *,
p  0.05; **, p  0.01; ***, p  0.001. GraphPad Prism 5 software
was used to perform all statistical analyses (mean  S.D.).
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